{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:38:30Z","timestamp":1771486710867,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s13555-020-00373-z","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T22:02:41Z","timestamp":1585864961000},"page":"351-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence"],"prefix":"10.1007","volume":"10","author":[{"given":"Jashin J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Menter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"issue":"5","key":"373_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.clindermatol.2006.07.006","volume":"24","author":"WA Myers","year":"2006","unstructured":"Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24(5):438\u201347.","journal-title":"Clin Dermatol"},{"issue":"3","key":"373_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"373_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CCID.S67534","volume":"7","author":"AS Lonnberg","year":"2014","unstructured":"Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251\u20139.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"373_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393.","journal-title":"Br J Dermatol"},{"issue":"4","key":"373_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"6","key":"373_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"373_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5\u00a0years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"373_CR8","unstructured":"Langley R, Sigugeirsson B, Szepietowski J, et al. Secukinumab maintains improvements in psoriasis through five years of treatment: a randomized extension of the phase III ERASURE and FIXTURE trials. Abstract presented at: American Academy of Dermatology 2019 [abstract 100052]."},{"issue":"1","key":"373_CR9","first-page":"2-012-0002-x","volume":"2","author":"BE Strober","year":"2012","unstructured":"Strober BE, Clay Cather J, Cohen D, et al. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 2. Dermatol Ther (Heidelb). 2012;2(1):2-012-0002-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"373_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","volume":"19","author":"M Amin","year":"2018","unstructured":"Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1\u201313.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"373_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijwd.2016.12.003","volume":"3","author":"ML Porter","year":"2017","unstructured":"Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21\u20135.","journal-title":"Int J Womens Dermatol"},{"issue":"5","key":"373_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archderm.141.5.601","volume":"141","author":"JE Murase","year":"2005","unstructured":"Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141(5):601\u20136.","journal-title":"Arch Dermatol"},{"issue":"1","key":"373_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2018","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2018;80(1):43\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"21 Suppl","key":"373_CR14","first-page":"S403","volume":"23","author":"JJ Wu","year":"2017","unstructured":"Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am J Manag Care. 2017;23(21 Suppl):S403\u201316.","journal-title":"Am J Manag Care"},{"issue":"5","key":"373_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/bjd.16901","volume":"179","author":"RB Warren","year":"2018","unstructured":"Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205\u20137.","journal-title":"Br J Dermatol"},{"key":"373_CR16","unstructured":"Cosentyx\u00ae (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2018."},{"key":"373_CR17","unstructured":"Novartis. Data on file (Cosentyx powder for solution for injection and solution for injection [secukinumab]\u00a0Periodic Safety Update Report [PSUR]; December 26, 2017\u2013December 25, 2018; 2019)."},{"issue":"7251","key":"373_CR18","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"AM Nybo Andersen","year":"2000","unstructured":"Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708\u201312.","journal-title":"BMJ"},{"issue":"2","key":"373_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13555-018-0232-7","volume":"8","author":"C Nardin","year":"2018","unstructured":"Nardin C, Colas M, Curie V, Pelletier F, Puzenat E, Aubin F. Pregnancy after tubal sterilization in a woman treated with biologics for severe psoriasis. Dermatol Ther. 2018;8(2):323\u20136.","journal-title":"Dermatol Ther"},{"issue":"2","key":"373_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ajd.12641","volume":"59","author":"M Rademaker","year":"2018","unstructured":"Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018;59(2):86\u2013100.","journal-title":"Australas J Dermatol"},{"issue":"suppl 1","key":"373_CR21","first-page":"AB232","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Warren RB, et al. Secukinumab retreatment shows rapid recapture of treatment response: an analysis of a phase 3 extension trial in psoriasis. J Am Acad Dermatol. 2017;76(suppl 1):AB232.","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"373_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537\u201341.","journal-title":"Arch Dermatol"},{"issue":"11","key":"373_CR23","doi-asserted-by":"publisher","first-page":"E2427","DOI":"10.3390\/ijms18112427","volume":"18","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):E2427.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"373_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/rheumatology\/kex510","volume":"57","author":"K Kostner","year":"2018","unstructured":"Kostner K, Prelog M, Almanzar G, Fesq H, Haas JP, Hugle B. Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology. 2018;57(5):936\u20138.","journal-title":"Rheumatology"},{"issue":"4","key":"373_CR25","doi-asserted-by":"publisher","first-page":"e12611","DOI":"10.1111\/dth.12611","volume":"31","author":"S Dogra","year":"2018","unstructured":"Dogra S, Bishnoi A, Narang T, Handa S. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018;31(4):e12611.","journal-title":"Dermatol Ther"},{"issue":"7","key":"373_CR26","first-page":"695","volume":"16","author":"MH Henderson Berg","year":"2017","unstructured":"Henderson Berg MH, Carrasco D. Injection site reactions to biologic agents used in psoriasis and psoriatic arthritis. J Drugs Dermatol. 2017;16(7):695\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"373_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jdv.12850","volume":"30","author":"C Phan","year":"2016","unstructured":"Phan C, Sigal ML, Esteve E, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"373_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","volume":"35","author":"A Korber","year":"2018","unstructured":"Korber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135\u201344.","journal-title":"Drugs Aging"},{"key":"373_CR29","unstructured":"World Health Organization. Tuberculosis. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Published September 18, 2018. Accessed Nov 18, 2018."},{"issue":"3","key":"373_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1128\/MMBR.00010-14","volume":"78","author":"NK Dutta","year":"2014","unstructured":"Dutta NK, Karakousis PC. Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev. 2014;78(3):343\u201371.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"6","key":"373_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","volume":"14","author":"F Cantini","year":"2015","unstructured":"Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimm Rev. 2015;14(6):503\u20139.","journal-title":"Autoimm Rev"},{"issue":"4","key":"373_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"373_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/09546634.2018.1443198","volume":"29","author":"EB Lee","year":"2018","unstructured":"Lee EB, Amin M, Man J, Egeberg A, Wu JJ. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review. J Dermatolog Treat. 2018;29(7):671\u20135.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"373_CR34","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2015.04.070","volume":"73","author":"KE Gilbert","year":"2015","unstructured":"Gilbert KE, Manalo IF, Wu JJ. Comment on \u201cTime to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors\u201d. J Am Acad Dermatol. 2015;73(3):e121.","journal-title":"J Am Acad Dermatol"},{"key":"373_CR35","doi-asserted-by":"crossref","unstructured":"Gilbert KE, Manalo IF, Wu JJ. Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors. Dermatol Online J. 2016;22(8).","DOI":"10.5070\/D3228032186"},{"issue":"8","key":"373_CR36","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1038\/cti.2017.34","volume":"6","author":"M Kammuller","year":"2017","unstructured":"Kammuller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017;6(8):e152.","journal-title":"Clin Transl Immunol"},{"issue":"12","key":"373_CR37","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/jdv.14454","volume":"31","author":"A Nast","year":"2017","unstructured":"Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris\u2014Update apremilast and secukinumab\u2014EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(12):1951\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"373_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PC van de Kerkhof","year":"2016","unstructured":"van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83\u201398.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"373_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14712598.2019.1622678","volume":"19","author":"M Megna","year":"2019","unstructured":"Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84\u00a0week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855\u201361.","journal-title":"Expert Opin Biol Ther"},{"issue":"suppl1","key":"373_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000501989","volume":"11","author":"S Ribero","year":"2019","unstructured":"Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(suppl1):23\u20138.","journal-title":"Case Rep Dermatol"},{"issue":"10","key":"373_CR41","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","volume":"15","author":"A Blauvelt","year":"2016","unstructured":"Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413\u201320.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"373_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000286131","volume":"220","author":"AD Cohen","year":"2010","unstructured":"Cohen AD, Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology. 2010;220(3):218\u201322.","journal-title":"Dermatology"},{"issue":"28","key":"373_CR43","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.3748\/wjg.v22.i28.6444","volume":"22","author":"C Bonifati","year":"2016","unstructured":"Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444\u201355.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"373_CR44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jaad.2012.04.036","volume":"67","author":"A Abramson","year":"2012","unstructured":"Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67(6):1349\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"373_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","volume":"148","author":"S Hsu","year":"2012","unstructured":"Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95\u2013102.","journal-title":"Arch Dermatol"},{"issue":"5","key":"373_CR46","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jaad.2015.07.023","volume":"73","author":"IF Manalo","year":"2015","unstructured":"Manalo IF, Gilbert KE, Wu JJ. Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis. J Am Acad Dermatol. 2015;73(5):881\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"373_CR47","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1111\/jdv.14416","volume":"31","author":"DJ No","year":"2017","unstructured":"No DJ, Amin M, Wu JJ. Adalimumab use in patients with psoriasis and hepatitis B: a case series. J Eur Acad Dermatol Venereol. 2017;31(12):e548\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"373_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2230.2009.03476.x","volume":"35","author":"SE Behnam","year":"2010","unstructured":"Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol. 2010;35(4):397\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"373_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","volume":"77","author":"I Snast","year":"2017","unstructured":"Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88\u201397.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"373_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2340\/00015555-2989","volume":"98","author":"HY Chiu","year":"2018","unstructured":"Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829\u201334.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"373_CR51","doi-asserted-by":"publisher","first-page":"e12601","DOI":"10.1111\/dth.12601","volume":"31","author":"F Peccerillo","year":"2018","unstructured":"Peccerillo F, Odorici G, Pellacani G, Conti A. Secukinumab: a positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatol Ther. 2018;31(4):e12601.","journal-title":"Dermatol Ther"},{"issue":"2","key":"373_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1684\/ejd.2016.2939","volume":"27","author":"S Yanagihara","year":"2017","unstructured":"Yanagihara S, Sugita K, Yoshida Y, Tsuruta D, Yamamoto O. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27(2):185\u20136.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"373_CR53","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","volume":"74","author":"SM Gallitano","year":"2016","unstructured":"Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS. J Am Acad Dermatol. 2016;74(5):974\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"373_CR54","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"K Ronholt","year":"2017","unstructured":"Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"373_CR55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","volume":"62","author":"K Menon","year":"2010","unstructured":"Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"373_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000478076","volume":"53","author":"A Al-Khalili","year":"2018","unstructured":"Al-Khalili A, Dutz JP. Immunosuppression\/infections across indications. Curr Probl Dermatol. 2018;53:28\u201336.","journal-title":"Curr Probl Dermatol"},{"issue":"11","key":"373_CR57","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1111\/jdv.14301","volume":"31","author":"SP Reddy","year":"2017","unstructured":"Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31(11):e481\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"373_CR58","first-page":"646","volume":"17","author":"V Di Lernia","year":"2019","unstructured":"Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019;17(6):646\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"373_CR59","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","volume":"86","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86(11):1014\u201321.","journal-title":"Neurology"},{"key":"373_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2017.02.012","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased incidence and prevalence of psoriasis in multiple sclerosis. Mult Scler Relat Disord. 2017;13:81\u20136.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"373_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-alpha blockers. Curr Neurol Neurosci Rep. 2017;17(4):36.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"373_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.msard.2018.08.029","volume":"26","author":"E Lommers","year":"2018","unstructured":"Lommers E, Depierreux F, Hansen I, Dive D, Maquet P. NMOSD with anti-MOG antibodies following anti-TNFalpha therapy: a case report. Mult Scler Relat Disord. 2018;26:37\u20139.","journal-title":"Mult Scler Relat Disord"},{"key":"373_CR63","first-page":"e112","volume":"46","author":"GT Assefa","year":"2018","unstructured":"Assefa GT, Kaneko S, Oguro H, Morita E. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. J Dermatol. 2018;46:e112\u20133.","journal-title":"J Dermatol"},{"issue":"7","key":"373_CR64","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","volume":"263","author":"E Havrdova","year":"2016","unstructured":"Havrdova E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287\u201395.","journal-title":"J Neurol"},{"issue":"5","key":"373_CR65","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.it.2011.02.007","volume":"32","author":"J Zepp","year":"2011","unstructured":"Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 2011;32(5):232\u20139.","journal-title":"Trends Immunol"},{"issue":"Suppl 3","key":"373_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jdv.12165","volume":"27","author":"C Pouplard","year":"2013","unstructured":"Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):36\u201346.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"373_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","volume":"151","author":"E Shelton","year":"2016","unstructured":"Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151(1):97\u2013109.e4.","journal-title":"Gastroenterology"},{"issue":"1","key":"373_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"373_CR69","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"RH Prabhala","year":"2010","unstructured":"Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385\u201392.","journal-title":"Blood"},{"issue":"2","key":"373_CR70","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/leu.2015.228","volume":"30","author":"RH Prabhala","year":"2016","unstructured":"Prabhala RH, Fulciniti M, Pelluru D, et al. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia. 2016;30(2):379\u201389.","journal-title":"Leukemia"},{"issue":"6","key":"373_CR71","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/ijc.24497","volume":"125","author":"E Derhovanessian","year":"2009","unstructured":"Derhovanessian E, Adams V, Hahnel K, et al. Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer. 2009;125(6):1372\u20139.","journal-title":"Int J Cancer"},{"issue":"9","key":"373_CR72","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/ijms17091433","volume":"17","author":"J Fabre","year":"2016","unstructured":"Fabre J, Giustiniani J, Garbar C, et al. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci. 2016;17(9):1433.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"373_CR73","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1074\/jbc.M109372200","volume":"277","author":"D Haudenschild","year":"2002","unstructured":"Haudenschild D, Moseley T, Rose L, Reddi AH. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem. 2002;277(6):4309\u201316.","journal-title":"J Biol Chem"},{"issue":"7","key":"373_CR74","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.bjc.6604963","volume":"100","author":"C Horlock","year":"2009","unstructured":"Horlock C, Stott B, Dyson PJ, et al. The effects of trastuzumab on the CD4+CD25+FoxP3+\u2009and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer. 2009;100(7):1061\u20137.","journal-title":"Br J Cancer"},{"issue":"11","key":"373_CR75","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-07-5164","volume":"14","author":"KS Sfanos","year":"2008","unstructured":"Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14(11):3254\u201361.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"373_CR76","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/pros.10238","volume":"56","author":"GE Steiner","year":"2003","unstructured":"Steiner GE, Newman ME, Paikl D, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171\u201382.","journal-title":"Prostate"},{"issue":"3","key":"373_CR77","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bbrc.2008.07.060","volume":"374","author":"B Zhang","year":"2008","unstructured":"Zhang B, Rong G, Wei H, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008;374(3):533\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"373_CR78","first-page":"10515","volume":"8","author":"Y Zeng","year":"2015","unstructured":"Zeng Y, Zhang Q, Wang H, et al. Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. Int J Clin Exp Med. 2015;8(7):10515\u201336.","journal-title":"Int J Clin Exp Med"},{"key":"373_CR79","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckl)"},{"issue":"sup1","key":"373_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/09546634.2018.1524818","volume":"29","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, D\u2019Adamio S, Campione E, Mazzilli S, Bianchi L, Talamonti M. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. J Dermatolog Treat. 2018;29(sup1):17\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"373_CR81","doi-asserted-by":"publisher","first-page":"e12607","DOI":"10.1111\/dth.12607","volume":"31","author":"A Mateu-Puchades","year":"2018","unstructured":"Mateu-Puchades A, Santos-Alarcon S, Martorell-Calatayud A, Pujol-Marco C, Sanchez-Carazo JL. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018;31(4):e12607.","journal-title":"Dermatol Ther"},{"issue":"6","key":"373_CR82","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/bjd.16252","volume":"178","author":"HJ Weng","year":"2018","unstructured":"Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178(6):1439\u201340.","journal-title":"Br J Dermatol"}],"updated-by":[{"DOI":"10.1007\/s13555-020-00392-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00373-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00373-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00373-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:30:13Z","timestamp":1710502213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00373-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00373-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-020-00392-w","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"26 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-020-00392-w","URL":"https:\/\/doi.org\/10.1007\/s13555-020-00392-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}